Extended-release amantadine for OFF-related dystonia in Parkinson's disease.

Abstract

INTRODUCTION:

Dystonia is a painful OFF-related complication in Parkinson's disease (PD) with limited treatment options.

METHODS:

Post-hoc analysis using pooled data from two extended-release amantadine pivotal trials and follow-on open-label extension. Dystonia was assessed using the Unified Dyskinesia Rating Scale (UDysRS) Part 2 and the Movement Disorder Society-Unified PD Rating Scale (MDS-UPDRS) item 4.6.

RESULTS:

Of 196 participants, 119 (60.7%) reported OFF-related dystonia at baseline per UDysRS. Twelve-week treatment with extended-release amantadine improved OFF dystonia (treatment differences vs placebo: UDysRS Part 2, -1.0 [-1.9,-0.1]; p = 0.03 and MDS-UPDRS Item 4.6, -0.3 [-0.6,-0.05]; p = 0.02). There was no correlation between changes in OFF time and changes in OFF dystonia. Double-blind improvements in OFF dystonia were sustained throughout the 2-year follow-up.

CONCLUSIONS:

Extended-release amantadine yielded a sustained reduction in OFF-related dystonia in PD patients that was independent from a reduction in OFF time. A randomized controlled trial is warranted to confirm these findings.

• Authors: Alberto J Espay, Jill L Ostrem, Andrea E Formella, Caroline M Tanner
• Journal: Parkinsonism & related disorders (Parkinsonism Relat Disord) Vol. 122 Pg. 106088 (May 2024) ISSN: 1873-5126 [Electronic] England
• PMID: 38461688 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Randomized Controlled Trial)
• Copyright: Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Amantadine
• Delayed-Action Preparations
• Antiparkinson Agents

Topics

• Humans
• Amantadine (administration & dosage)
• Parkinson Disease (complications, drug therapy)
• Male
• Female
• Delayed-Action Preparations
• Dystonia (drug therapy, etiology)
• Aged
• Middle Aged
• Antiparkinson Agents (administration & dosage)
• Double-Blind Method